← Eichor
Condition: Hereditary Amyloidosis Transthyretin Related Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hereditary Amyloidosis Transthyretin Related

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Exercise in Hereditary ATTR (ATTRv) Amyloidosis
NA · 1 location(s) · University of Maia · NCT07033715ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Phase N/A · 40 location(s) · Alnylam Pharmaceuticals · NCT04561518Comprehensive Program for Hereditary Transthyretin Amyloidosis
Phase N/A · 1 location(s) · Hospital de Alta Complejidad en Red · NCT07213297To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transth
Phase 4 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06940336Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Phase 2 · 1 location(s) · Oregon Health and Science University · NCT05758493Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
NA · 1 location(s) · Massachusetts General Hospital · NCT05577819A Non-interventional Cohort Safety Study of Patients With hATTR-PN
Phase N/A · 26 location(s) · Akcea Therapeutics · NCT04850105TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos
Phase 3 · 41 location(s) · Alnylam Pharmaceuticals · NCT07223203A Phase 3 Study of NTLA-2001 in ATTRv-PN
Phase 3 · 14 location(s) · Intellia Therapeutics · NCT06672237MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Phase 3 · 132 location(s) · Intellia Therapeutics · NCT06128629Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients
NA · 1 location(s) · Assistance Publique Hopitaux De Marseille · NCT06845644Pan-Amyloid PET/CT in Various Amyloid-Related Disease
Phase N/A · 2 location(s) · Tianjin Medical University · NCT07130565Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients Wit
Phase N/A · 1 location(s) · University of Texas Southwestern Medical Center · NCT07196839A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopa
Phase N/A · 1 location(s) · Bayer · NCT07235462Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Phase N/A · 3 location(s) · University of Texas Southwestern Medical Center · NCT05489549Exploring Biomarkers in Hereditary Transthyretin Amyloidosis
NA · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05929209The Eplontersen Pregnancy and Lactation Outcomes Study
Phase N/A · 1 location(s) · AstraZeneca · NCT07205666Phenotyping and Characterization of wtATTR-CM (TRACE 1)
Phase N/A · 1 location(s) · Steen Hvitfeldt Poulsen · NCT06291805Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Phase N/A · 82 location(s) · AstraZeneca · NCT06465810Phenotypic Manifestations of Hereditary ATTR Amyloidosis
Phase N/A · 2 location(s) · Hospital 9 de Julio de Las Breñas · NCT07124377An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Progra
NA · 1 location(s) · Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06907186Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy
NA · 1 location(s) · Clinique Saint Jean, France · NCT07644325Cardiovascular Multimodality Imaging Study
Phase N/A · 1 location(s) · Montefiore Medical Center · NCT06610019Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
Phase N/A · 4 location(s) · Intellia Therapeutics · NCT05697861Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Patho
Phase 3 · 103 location(s) · Eidos Therapeutics, a BridgeBio company · NCT06563895
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.